Decitabine
T-cell/Myeloid Mixed Phenotype Acute Leukemia
The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the T-cell/Myeloid Mixed Phenotype Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE M.D. Anderson Cancer Center | Phase 2 | B |
(+)-VINCRISTINE M.D. Anderson Cancer Center | Phase 2 | B |
Sorafenib M.D. Anderson Cancer Center | Phase 2 | B |
Clofarabine M.D. Anderson Cancer Center | Phase 2 | B |
Cytosin-Arabinosid yuejun Liu | Phase 2 | B |
View all 10 →
Same molecule, other indications
Decitabine is also rated in:
acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant
BB
Indicative ·
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →